Kevin Davidge

Mr. Davidge has 20 years of executive financial leadership for a wide variety of healthcare/life science companies in the biotechnology, medical imaging, and diagnostics segments. Most recently, Mr. Davidge was CFO for HX Diagnostics, a start-up company developing point-of-care diagnostics tests for infectious diseases. HX was merged into NexusDx in 2009. Prior to that, Mr. Davidge served as CFO for two medical imaging companies, R2 Technology and ZONARE Medical Systems. Revenues in both companies ramped from zero to $30–$60 million within four years of product launch. Earlier in his career, Mr. Davidge was CFO at Athena Neurosciences, a publicly traded biopharmaceutical company where revenues grew from zero to $70 million in four years. Athena was sold to Elan in 1996 for $600 million.Mr. Davidge has extensive fundraising, M&A, and product licensing experience, having raised over $200 million in equity, debt and off balance sheet financings. Mr. Davidge spent the first nine years of his career in the international public accounting firm of KPMG. Mr. Davidge graduated from UC Berkeley Phi Beta Kappa, summa cum laude with a B.S. in Business Administration.